|
|
|
| home > ebr > Winter 2011 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
|
|
Partnering is the lifeblood of the biotech and pharmaceutical industries and, as the industry expands, Robert Lee Kilpatrick from TVG discusses the ideal elements for successful collaborations.
|
|
|
|
|
Xavier Tizon at Oncodesign makes a strong case for the untapped potential of imaging biomarkers and how they can be applied in future drug development stages.
|
|
|
Simon Webster from Avacta Group PLC considers the benefits of maintaining physical stability of candidate therapeutic proteins at an early stage in the discovery process, and highlights pioneering techniques for monitoring conformational and colloidal stability.
|
|
|
|
For companies facing up to the move from proof-of-concept to proof-of-differentiation, Markus Thunecke from Catenion considers the three levels of evaluation that should be considered.
|
|
|
Kai Lamottke at Bicoll GmbH, Christophe Ripoll at Naturalpha and Robert Walczak at Genfit SA consider if natural product programmes are ready to challenge the traditional drug cycle process.
|
|
|
By encouraging others to develop their own drugs using a patented technology, the patent owner has the potential to develop substantial revenues, observe Michael R Ward,Otis Littlefield and Anita Choi from Morrison & Foerster LLP.
|
|
|
Sekhar Medisetti at GlobalData takes a look at the niche market for Type 1 diabetes, the continuous challenge posed by patient compliance, and the problematic issue of delivery methods for insulin products.
|
|
|
|
Bill Whitford of Thermo Scientific Cell Culture and BioProcessing analyses the advantages of single-use bioreactors and the supply and performance features they offer in process development.
|
|
|
| In response to the danger posed by bacterial retention testing, Martha Folmsbee, Morven McAlister and Jerold Martin at Pall Life Sciences compare and contrast the various tests for predicting and confirming retention. |
|
|
Amin Omar at Innovotech highlights the need for finding the most suitable antimicrobial agent to avoid the potential problems of biofilm infections.
|
|
|
|
Following the launch of the Smart SME Market Validation Programme, Rebecca Philpot from the State Government of Victoria, Australia, considers other ways in which the city is changing to better accommodate the biotech industry.
|
|
|
|
|
|
 |
|
|
 |
Industry Events |
 |
BIO-Europe® 2012
12-14 November 2012, Congress Center Hamburg, Hamburg, Germany
Building value through partnerships
BIO-Europe® is the
preeminent partnering conference for the life sciences. BIO-Europe brings
together international decision makers from the biotechnology, pharmaceutical
and financial sectors, offering networking opportunities, workshop and panel
participation, a high profile exhibition, and private, prescheduled one-to-one
meetings.
More info >> |
|
 |
News and Press Releases |
 |
GE Healthcare and Refine Technology sign supply and distribution agreement to support drive for continuous processing in biopharmaceutical manufacture
GE Healthcare, the healthcare business of GE (NYSE: GE) has signed a worldwide supply and distribution agreement with Refine Technology, a manufacturer and supplier of novel filtration systems for use in biopharmaceutical manufacturing. Under the terms of the agreement, GE Healthcare will supply Refine Technology with its innovative hollow fiber filtration cartridges for use with Refine Technology’s ATF™ system.
More info >> |
|
__________________________
__________________________
__________________________
__________________________
__________________________
|
